Presence of glucose in dialyzing fluid and synthesis of selected lipoxygenase-derived eicosanoids during hemodialysis

International Urology and Nephrology

Volumn 44, Issue 6, 2012, Pages 1799-1804

  Dołȩgowska, Barbara ^a   Błogowski, Wojciech ^a   Stȩpniewska, Joanna ^a   Safranow, Krzysztof ^a   Jakubowska, Katarzyna ^a   Olszewska, Maria ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Chronic kidney disease; Eicosanoids; Hemodialysis; HETE; Lipoxygenase

Indexed keywords

C REACTIVE PROTEIN; DIALYSIS FLUID; GLUCOSE; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; HEMODIALYSIS FLUID; LIPOXYGENASE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME SYNTHESIS; FATTY ACID ANALYSIS; FATTY ACID SYNTHESIS; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MALE; TREATMENT OUTCOME; UPREGULATION; BIOSYNTHESIS; CHEMISTRY; CHRONIC KIDNEY FAILURE; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

FEMALE; GLUCOSE; HEMODIALYSIS SOLUTIONS; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; LIPOXYGENASE; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84877608450     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-011-0089-5     Document Type: Article

References (22)

1. Remport A, Keszei A, Vamos EP, et al. (2011) Association of pre-transplant dialysis duration with outcome in kidney transplant recipients: a prevalent cohort study. Int Urol Nephrol 43:215-224
2. Chung AW, Yang HH, Kim JM, et al. (2009) Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 120:792-801
3. Rysz J, Banach M, Stolarek RA, et al. (2011) Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Int Urol Nephrol 43:491-498
4. Granata S, Zaza G, Simone S, et al. (2009) Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 10:388
5. Zaza G, Pontrelli P, Pertosa G, et al. (2008) Dialysis-related systemic microinflammation is associated with specific genomic patterns. Nephrol Dial Transplant 23:1673-1681
6. Taccone-Gallucci M, Manca-di-Villahermosa S, Battistini L, et al. (2006) N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity. Kidney Int 69:1450-1454
7. Cristol JP, Maggi MF, Bosc JY, et al. (1997) Oxidative stress and chronic renal insufficiency: what can be a prophylactic approach? C R Seances Soc Biol Fil 191:603-616
8. Dołȩgowska B, Błogowski W, Safranow K, Domanski L, Jakubowska K, Olszewska M (2010) Lipoxygenase-derived hydroxyeicosatetraenoic acids - novel perioperative markers of early post-transplant allograft function? Nephrol Dial Transplant 25:4061-4067
9. Dolegowska B, Stepniewska J, Ciechanowski K, et al. (2007) Does glucose in dialysis fluid protect erythrocytes in patients with chronic renal failure? Blood Purif 25:422-429
10. Dolegowska B, Blogowski W, Chlubek D (2006) The effect in vitro of glucose on erythrocyte resistance to hemolysis. Ann Acad Med Stettin 52:25-28
11. Stepniewska J, Dolegowska B, Ciechanowski K, et al. (2006) Erythrocyte antioxidant defense system in patients with chronic renal failure according to the hemodialysis conditions. Arch Med Res 37:353-359
12. Dolegowska B, Blogowski W, Kedzierska K, et al. (2009) Platelets arachidonic acid metabolism in patients with essential hypertension. Platelets 20:242-249
13. Dolegowska B, Blogowski W, Domanski L (2009) Dynamics of thromboxane level changes during early phase of allograft reperfusion. Clin Transplant 23:716-722
14. Dołȩgowska B, Błogowski W, Domański L (2009) Is it possible to predict the early post-transplant allograft function using 20-HETE measurements? A preliminary report. Transpl Int 22:546-553
15. Dołȩgowska B, Błogowski W, Domański L (2010) Clinical evidence of the association between serum perioperative changes in xanthine metabolizing enzymes activity and early post-transplant kidney allograft function. J Am Coll Surg 211:587-595
16. Mallat Z, Nakamura T, Ohan J, et al. (1999) The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes and plaque instability in human carotid atherosclerosis. J Clin Invest 103:421-427
17. Kuhn H, Heydeck D, Hugou I, et al. (1997) In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest 99:888-893
18. Shen J, Herderick E, Cornhill JF, et al. (1996) Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 98:2201-2208
19. Miller LM, Sood MM, Sood AR, et al. (2010) Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients. Int Urol Nephrol 42:1007-1014
20. Paraskevas KI, Kotsikoris I, Koupidis SA, Tzovaras AA, Mikhailidis DP (2010) Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. Int Urol Nephrol 42:999-1006
21. Wittwer J, Hersberger M (2007) The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 77:67-77
22. Hase H, Joki N, Ishikawa H, et al. (2006) Independent risk factors for progression of coronary atherosclerosis in hemodialysis patients. Ther Apher Dial 10:321-327